Desn.S
Desn is a pharmaceutical company that develops and commercializes innovative therapies, primarily in the field of oncology, with a focus on targeted treatments for specific patient populations.
Business. Desn is a pharmaceutical company that develops and commercializes innovative therapies, primarily in the field of oncology, with a focus on targeted treatments for specific patient populations.
Analyst recommendations
2 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Desn is a pharmaceutical company that develops and commercializes innovative therapies, primarily in the field of oncology, with a focus on targeted treatments for specific patient populations.
Desn maintains a strong liquidity position, with a current ratio of 2.67 and CHF 147.77 million in cash and equivalents, which supports its short-term obligations. The company's debt-to-equity ratio is 0.13, indicating a conservative capital structure with limited leverage. Free cash flow is minimal at CHF 551,000, suggesting that operating cash flow is being largely reinvested in the business or used to service obligations.
Profitability metrics show a return on equity of 10.64% and a return on assets of 7.82%, which are strong indicators of efficient capital use and asset management. Gross profit of CHF 259.49 million and operating income of CHF 118.42 million reflect a healthy margin structure, although the company's performance should be benchmarked against industry peers to assess relative competitiveness.
Geographically, Desn's revenue is concentrated in a few key markets, with no detailed breakdown provided in the available data. The company's exposure to specific regions may influence its performance, particularly in light of regulatory and market access dynamics in the pharmaceutical industry.
Looking ahead, Desn is projected to maintain a stable growth trajectory, with no significant revenue changes expected in the next fiscal year. The company's capital expenditure of CHF -127.07 million indicates a focus on cost management and operational efficiency, which may support long-term value creation.
Risk factors for Desn include the inherent volatility in the pharmaceutical sector, such as regulatory changes, patent expirations, and competitive pressures. The company's low dilution risk and strong liquidity position mitigate some of these concerns, but ongoing monitoring of capital structure and cash flow generation is warranted.
Recent filings and transcripts do not indicate any material events that would significantly alter the company's strategic direction or financial outlook. Analysts have provided a mean price target of CHF 365.00, with a recommendation of 2.50 (a "hold" rating), suggesting a neutral stance on the stock.
- Desn has a strong liquidity position with a current ratio of 2.67 and CHF 147.77 million in cash and equivalents.
- The company's return on equity of 10.64% and return on assets of 7.82% indicate efficient capital use and asset management.
- Desn's capital structure is conservative, with a debt-to-equity ratio of 0.13 and limited leverage.
- Analysts have assigned a mean price target of CHF 365.00, with a "hold" recommendation, suggesting a neutral outlook.
- The company's growth trajectory is expected to remain stable, with no significant revenue changes projected in the next fiscal year.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 8,98 |
| Revenue | —no estimate | —no estimate | 459,1M CHF |
| Operating income | —no estimate | —no estimate | 141,0M CHF |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- DESN.S Market data — financials · 2026-05-27
- Dottikon ES Holding AG Market data — analyst estimates · 2026-05-27